Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$6.1B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating within the health care sector, Kiniksa's work is particularly relevant as the demand for effective treatments continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help assess its financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding how well Kiniksa is expanding its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating estimates and resulting in a 23.48% stock increase the following day. However, revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Kiniksa has shown a history of beating EPS estimates but lacks guidance for this quarter. Investors will be keenly watching for any signs of revenue growth.

Bull Case

If Kiniksa continues its trend of beating EPS estimates and provides positive updates on its product pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides no guidance, it could lead to a decline in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS this quarter?

Given the company's history of EPS surprises, this number will be crucial for market sentiment.

Are there any updates on the product pipeline?

Investors will be looking for insights into future revenue streams and the potential for new product launches.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Kiniksa's product pipeline to deliver unexpected revenue growth this quarter.

Supporting Evidence

Kiniksa has a history of surprising on EPS, as seen in the last quarter.

The options market is pricing in a significant move, indicating that investors expect volatility.

Recent trends in the biotech sector suggest a rebound in investor confidence.

Key Risk

If the reported EPS exceeds $0.30, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Kiniksa's ability to maintain its earnings momentum and provide clarity on future growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate strong profitability.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 6.58%, as the market reacts negatively to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of key products in the pipeline.
2Updates on regulatory approvals or clinical trial results.
3Insights into market conditions and competitive landscape.
4Management's outlook on revenue growth for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help assess its financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding how well Kiniksa is expanding its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating estimates and resulting in a 23.48% stock increase the following day. However, revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Kiniksa has shown a history of beating EPS estimates but lacks guidance for this quarter. Investors will be keenly watching for any signs of revenue growth.

Bull Case

If Kiniksa continues its trend of beating EPS estimates and provides positive updates on its product pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides no guidance, it could lead to a decline in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS this quarter?

Given the company's history of EPS surprises, this number will be crucial for market sentiment.

Are there any updates on the product pipeline?

Investors will be looking for insights into future revenue streams and the potential for new product launches.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Kiniksa's product pipeline to deliver unexpected revenue growth this quarter.

Supporting Evidence

Kiniksa has a history of surprising on EPS, as seen in the last quarter.

The options market is pricing in a significant move, indicating that investors expect volatility.

Recent trends in the biotech sector suggest a rebound in investor confidence.

Key Risk

If the reported EPS exceeds $0.30, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Kiniksa's ability to maintain its earnings momentum and provide clarity on future growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate strong profitability.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 6.58%, as the market reacts negatively to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of key products in the pipeline.
2Updates on regulatory approvals or clinical trial results.
3Insights into market conditions and competitive landscape.
4Management's outlook on revenue growth for the upcoming quarters.